- Home
- IRS vs COGT Comparison
IRS vs COGT Comparison
Compare IRS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- COGT
- Stock Information
- Founded
- IRS 1943
- COGT 2014
- Country
- IRS Argentina
- COGT United States
- Employees
- IRS N/A
- COGT N/A
- Industry
- IRS Homebuilding
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- COGT Health Care
- Exchange
- IRS Nasdaq
- COGT Nasdaq
- Market Cap
- IRS 1.1B
- COGT 1.1B
- IPO Year
- IRS 1994
- COGT 2018
- Fundamental
- Price
- IRS $15.60
- COGT $12.07
- Analyst Decision
- IRS Strong Buy
- COGT Strong Buy
- Analyst Count
- IRS 1
- COGT 9
- Target Price
- IRS $12.62
- COGT $20.25
- AVG Volume (30 Days)
- IRS 173.8K
- COGT 5.1M
- Earning Date
- IRS 09-02-2025
- COGT 08-05-2025
- Dividend Yield
- IRS 6.40%
- COGT N/A
- EPS Growth
- IRS N/A
- COGT N/A
- EPS
- IRS 0.20
- COGT N/A
- Revenue
- IRS $308,539,877.00
- COGT N/A
- Revenue This Year
- IRS N/A
- COGT N/A
- Revenue Next Year
- IRS N/A
- COGT N/A
- P/E Ratio
- IRS $7.03
- COGT N/A
- Revenue Growth
- IRS N/A
- COGT N/A
- 52 Week Low
- IRS $7.93
- COGT $3.72
- 52 Week High
- IRS $17.67
- COGT $12.97
- Technical
- Relative Strength Index (RSI)
- IRS 65.19
- COGT 78.82
- Support Level
- IRS $14.29
- COGT $11.93
- Resistance Level
- IRS $15.07
- COGT $12.79
- Average True Range (ATR)
- IRS 0.47
- COGT 0.74
- MACD
- IRS 0.12
- COGT 0.03
- Stochastic Oscillator
- IRS 98.66
- COGT 76.56
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.